Navigation Links
Lawson scientist presents joint pain treatment 2.0
Date:8/12/2011

LONDON, ON Osteoarthritis (OA) is the most common form of arthritis, affecting roughly 10% of Canadians. This degradation of the joints is painful and crippling, especially when it affects the knee. Although there are viable OA treatment options, they are short-lived and can have serious side-effects. According to Lawson Health Research Institute's Dr. Robert Petrella, principal investigator in the COR1.0 study, the next generation of OA treatment has arrived.

When patients have OA in the knee, the fluid in their joint breaks down, causing pain and preventing natural shock absorption. To treat this condition, gel-like substances called "viscosupplements" are injected into the knee. This acts as a supplement for the fluid loss and provides temporary pain relief. In the COR1.0 study, Dr. Petrella and his colleagues compared Synvisc-One, the leading market viscosupplement for OA in the knee, to Hydros-TA Joint Therapy. Hydros-TA is a unique dual-action treatment combining steroids within a viscosupplement. It is believed to provide faster acting, longer lasting pain relief than either treatment alone.

To compare and evaluate the safety and effectiveness of both treatments, Dr. Petrella and his team conducted a double-blinded, multi-center clinical trial. Across eight sites in Canada, Belgium, and The Netherlands, a total of 98 patients were given a single injection and then monitored for six months. Results show trends suggesting Hydros-TA provides superior pain relief and improved function, causes fewer adverse events, and has a higher overall response rate. For patients, this could mean greater, more consistent pain relief with faster onset.

"Patients are really searching for better options for osteoarthritis therapy," Dr. Petrella explains. "Hydros-TA takes effect very quickly and lasts longer than other available therapies, allowing patients to achieve and sustain a higher quality of life."

Dr. Petrella and Carbylan BioSurgery Inc., the makers of Hydros-TA, are planning a larger multi-center trial to take place in the United States next year.


'/>"/>

Contact: Sonya Gilpin
sonya.gilpin@lawsonresearch.com
519-685-8500 x75852
Lawson Health Research Institute
Source:Eurekalert

Related medicine news :

1. Scientists explore the intersection of health, society and microbial ecology
2. Scientists explain unique activity of TB drug pyrazinamide
3. BIDMC scientists receive Challenge Awards from Prostate Cancer Foundation
4. USC scientist develops virus that targets HIV
5. Scientists Take Navel-Gazing to New Level
6. Johns Hopkins scientists map genes for common form of brain cancer
7. Scientists May Have Found Missing Link to Common Brain Cancer
8. Have we met before? Scientists show why the brain has the answer
9. Scientists Warn of New Multidrug-Resistant Salmonella
10. Johns Hopkins scientists begin first-of-its-kind research to create blood platelets from stem cells
11. Scientists show swamp gas protects blood vessels from complications of diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... ... ... Stern Environmental Group , of Secaucus, New Jersey, working in conjunction ... Real Time Monitoring (RTM) Device. Stern Environmental Group will sell the first monitoring ... use in dormitories, shelters, and nursing homes for real time bedbug monitoring in May ...
(Date:5/24/2016)... ... 2016 , ... Sterling Global Products is launching a Kickstarter campaign focused on ... dispenser. The campaign kick-off video is located via this link https://youtu.be/WsO4qz2odco . The ... is to raise $1,000 per day for a total of $25,000. The funds will ...
(Date:5/24/2016)... ... May 24, 2016 , ... To better understand the impact of lung cancer ... gender differences in lung cancer. Today, the Lung Association announced Sharad Goyal, MD , ... Award, funded by the American Lung Association’s LUNG FORCE initiative, which raises awareness of ...
(Date:5/24/2016)... ... May 24, 2016 , ... i2i, ... identity and website at its “Transforming Outcomes” User Conference in Las Vegas on ... i2i’s ongoing success to set the market standard for meaningful population health management. ...
(Date:5/24/2016)... ... May 24, 2016 , ... ... enabled solutions and managed services today announced a strategic partnership with Five9 ... center market. , Altura, one of Avaya’s largest Platinum Business Partners, is ...
Breaking Medicine News(10 mins):
(Date:5/24/2016)...   , Study met both ... superiority in , Excellent plus Good ... of the ascending colon   , ... today announced new positive data from the phase III MORA study ... 2 litre PEG with ascorbate. The study met both primary endpoints ...
(Date:5/24/2016)... 2016  NxStage Medical, Inc. (Nasdaq: NXTM ... renal care, today announced that Jeffrey H. Burbank ... following schedule of investor conferences. Where applicable, a webcast ... http://ir.nxstage.com/ .   ... NY           Friday, June 10, 2016 1:30 p.m. ET ...
(Date:5/24/2016)... The innovator of COMBO ... s first dual therapy stent, introduces catheters for ... OrbusNeich, a global company specializing in the provision of ... products to treat peripheral artery disease. The JADE™ and ... for lower limb and arteriovenous (AV) fistula intervention. ...
Breaking Medicine Technology: